Described are methods of decreasing vascular inflammation in a subject suffering from a chronic autoimmune or chronic inflammatory disease by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Also described are methods of treating inflammation associated with an implant (e.g., a breast implant) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Further described are methods of treating psoriasis (e.g., active plaque psoriasis) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 80 mg/day to about 160 mg/day, optionally administered in two daily sub-doses, and wherein the psoriasis prior to the administering the VB-201 is characterized by a body surface area (BSA) from about 20% to about 30 %, or a PASI score that is from about 10 to about 20 (i.e., moderate to severe psoriasis).Linvention concerne des procédés de diminution de linflammation vasculaire chez un sujet souffrant dune maladie auto-immune chronique ou inflammatoire chronique par administration au sujet dune quantité thérapeutiquement efficace de VB-201, la quantité thérapeutiquement efficace étant denviron 20 mg/jour à environ 160 mg/jour, administrée facultativement en deux sous-doses quotidiennes. Linvention concerne également des procédés de traitement de linflammation associée à un implant (par exemple, un implant mammaire) chez un sujet par administration au sujet dune quantité thérapeutiquement efficace de VB-201, la quantité thérapeutiquement efficace étant denviron 20 mg/jour à environ 160 mg/jour, administrée facultativement en deux sous-doses quotidiennes. Linventi
